alexa Supplementation of Vitamin D in Patients with Sickle Cell Bone Disease: A Dbate or a Combate? | Open Access Journals
ISSN: 2329-8790
Journal of Hematology & Thromboembolic Diseases
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Supplementation of Vitamin D in Patients with Sickle Cell Bone Disease: A Dbate or a Combate?

Farid Menaa*
Executive Director and Professor, Fluorotronics, Inc. CA, USA
Corresponding Author : Farid Menaa
Executive Director and Professor
Fluorotronics, Inc. CA, USA Tel: (760) 599-9496
E-mail: [email protected]
Received July 29, 2014; Accepted July 29, 2014; Published July 31, 2014
Citation: Menaa F (2014) Supplementation of Vitamin D in Patients with Sickle Cell Bone Disease: A D-bate or a Combate?. J Hematol Thrombo Dis 2:e115 doi:10.4172/2329-8790.1000e115
Copyright: © 2014 Menaa F. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Related article at
DownloadPubmed DownloadScholar Google

Visit for more related articles at Journal of Hematology & Thromboembolic Diseases

Abstract

After its discovery as a genetically inherited hemoglobinopathy one hundred years ago, finding a widely available cure for sickle cell anemia (SCA, HbSS) still remains a challenge and the disease requires multi-disciplinary theranostic approaches (Menaa et al., 2013; Menaa, 2014). Indeed, more effort and resources to promptly find alternative therapeutics and/or adjuvants (e.g. nutraceutics) to HU

Editorial
After its discovery as a genetically inherited hemoglobinopathy one hundred years ago, finding a widely available cure for sicklecellanemia (SCA, HbSS) still remains a challenge and the disease requires multi-disciplinary theranostic approaches. Indeed, more effort and resources to promptly find alternative therapeutics and/or adjuvants (e.g. nutraceutics) to HU, the orphan Food and Drug Administration (FDA)-approved drug, are mandatory as a means of decreasing mortality, morbidity and improving quality of life among SCA patients [1-3].
Importantly, since over three decades, a growing body of studies [4-19] have reported links between deficiency in vitamin D (25-hydroxy vitamin D; 25-OHD, de facto a hormone), an endocrine organ dysfunction commonly detected in SCA patients, and its health consequences. Thereby, it has been globally showed that children, adolescents or adults patients with SCA (up to 65%) have higher susceptibility/prevalence (i.e. about 3-4 times) of more profound deficiency in vitamin D (i.e. serum level<15 ng/mL) than healthy individuals (i.e. up to 90% with serum levels<30 ng/mL) [2,10-12,20]. Nevertheless, genetics, social, geographical, seasonal, nutritional and physiological influences, among others, are interconnected and contribute to the life adaptation, specie evolution, chronic diseases epidemiology and their clinical complexity [7,21,22]. Hence, one should always avoid any generalization considering that sometimes HbSS patients matched with HbAA control patients may elicit no significant differences in vitamin D levels [6], and a slight bone mineral density (BMD) decrease could be found in SCA pre-adolescent female children independently of disease severity, vitamin D deficiency, low calcium intake or bone hyper-resorption but maybe due to abnormal bone formation [12].
In general, the etiologies of vitamin D deficiency are poorly defined in SCA patients (e.g. often attributed to increased skin melanin concentrations, lower dietary intake, reduced levels of physical activity, highly prevalent bone resorption markers), but often result in bony changes and bone fragility (e.g. rickets, osteomalacia, incomplete ossification, low BMD, osteoporosis, osteonecrosis, fracture risk, chronic musculoskeletal pain and weakness, low BMD associated-vasoocclusive crises, hyperparathyroidism) [3,12,15,16,19]. Although vitamin D is essential for normal absorption of calcium, for calcium and bone mass homeostasis, the significance and optimal means of correction of vitamin D deficiency were poorly studied. Hence, it is worth to note that due to the lack of prospective and randomized studies in these patient populations, there are currently not enough recommendations for macro- or micronutrients (e.g. calcium and vitamin D) supplementation (e.g. ergocalciferol aka vitamin D2 which is found in vegetables, cholecalciferol alias vitamin D3 which is present in some fishes and meats) in this population. Interestingly, a recent study [19] showed that: (i) 91% of children had vitamin D levels lower than 20 ng/mL; (ii) intramuscular ergocalciferol (7729 IU/Kg) and oral cholecalciferol (5234 IU/Kg) supplementations resulted in significant increases (2.82 versus 6.44 ng/L/IU/Kg, respectively) of vitamin D blood concentration to normal levels during 4 months when administrated for about 4 days, suggesting a much better increment with oral cholecalciferol compared to intramuscular ergocalciferol. This study is in line with another recent clinical investigation [14] which compared a 6-week course of oral high-dose cholecalciferol (4000-100,000 IU per week) with a placebo, and showed that cholecalciferol achieved higher serum vitamin D level in SCA subjects that subsequently experienced fewer pain days per week and had higher physical activity quality-of-life scores. Besides, other pertinent studies show that treatment of adult SCD with vitamin D and calcium can restore vitamin D levels to normal and improve BMD, albeit markers of bone resorption remained unchanged [9]. Also and consistently, treatment with high-dose vitamin D resulted in complete resolution of chronic pain symptoms and improvement in BMD [20,23].
Eventually, clinical recommendations contribute to the creation of many opportunities for possible therapeutic and chemopreventive applications. These shall include early interventions and routine check-ups in SCA patients, such as: (i) blood levels monitoring of parathyroid hormone (PTH) which serum concentrations are expected to be supranormal, 25 Hydroxyvitamin D (25OHD) synthetized in liver from skin or Vitamin D2/D3 supplementation and 1,25 Dihydroxyvitamin D (1,25(OH)2D) subsequently generated in liver, calmodulin (CaM) and calcium (Ca2+) due to hypocalcaemic tendency, as well as markers of bone resorption and formation (e.g. C-terminal telopeptides of pro-collagen type I, type I-collagen, bone-specific alkaline phosphatase, osteocalcin); (ii) BMD estimation by dual-energy X-ray absorptiometry (DXA) at lumbar spine and proximal femur/femoral neck, lumbar spine, and distal third of the ulna plus radius; (iii) determination of each patient´s habits (e.g. solar exposition which should be about 20-30 minutes daily without anti-UV cream; nutrition including vitamin D supplementation (=10.000 UI cholecalciferol every week, although the optimal dosing remains to be determined in spite of its wide safety window). In this regard, it is important to keep in mind that the presence of pro-drugs (e.g. butyrate, phenylbutyrate) can enhance vitamin D systemic bioavailability [24], and so, shall be vitamin D dosing shall be tailored in a personalized fashion according to blood vitamin D concentrations of each patient in order to avoid any adverse-effects (“hypervitaminose D”); Physical activity (e.g. running or walking about 30 minutes per day); Social life considerations (e.g. stimulation/coaching the SCA patients for better social interactions).
Further studies in SCA patients are warranted to evaluate the effects of vitamin D repletion on clinical outcomes such as bone density, chronic musculoskeletal pain, and functional status. In addition to randomized and prospective studies, genomic and epidemiological investigations as well as meta-analyses shall be of a great help to better prevent SCA complications, efficiently and safely manage patients with sickle cell bone disease in a personalized manner.
References
























Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 11979
  • [From(publication date):
    July-2014 - Jul 26, 2017]
  • Breakdown by view type
  • HTML page views : 8161
  • PDF downloads :3818
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords